Clinical trials: Addiction, Substance
- Condition Addiction, Substance
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Substance Dependence
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Study to investigate the safety, tolerability and pharmacokinetics of GSK598809 in otherwise healthy volunteers. This study is required because this drug is being developed for the treatment of nicotine dependence.
- Trial name
- NCT00728052
- Testing
- GSK598809
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00605241
- Testing
- GSK598809
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcoholism
To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
A total of at least 48 healthy subjects with a history of social drinking will be recruited into this single-centre, randomized, double-blind, cross-over study.
- Trial name
- NCT01738867
- Testing
- GSK1521498, Naltrexone (NTX)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nicotine Addiction, Drug Addiction
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT05440721
- Testing
- Treatment A with device Clickotine® (Active intervention), Treatment B with smoking education (control)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Nicotine Addiction, Cigarette Smoking
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of…
- Trial name
- DUAL (NCT02870218)
- Testing
- Smoking research cigarettes with e-cigarette, Nicotine discrimination thresholds
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Addiction
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of a single day dosing and a separate multiple day dosing of 18-MC HCl administered orally, each part of the study having a different set of healthy…
- Trial name
- NCT04292197
- Testing
- 18-MC Compound
- Where
- Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Definium Therapeutics US, Inc.
Cocaine Use Disorder, Substance Use Disorders
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
- Conditions
- Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
- Trial name
- NCT06025396
- Testing
- Cohort 1 - TMP-301, Cohort 2 - TMP-301, Cohort 3 - TMP-301
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tempero Bio, Inc.
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pain, Pain, Acute
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and…
- Conditions
- Pain, Pain, Acute, Pain, Chronic, Pain, Neuropathic
- Trial name
- NCT04080037
- Testing
- Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Substance Dependence
GSK618334 Repeat Dose Study
The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
- Trial name
- NCT01036061
- Testing
- GSK618334 Low Dose, GSK618334 PET subjects, GSK618334 Medium Dose
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Abuse and Addiction
Nalmefene Implant in Healthy Subjects
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks.
- Trial name
- NCT07325279
- Testing
- 1 Nalmefene implant, 2 Nalmefene implants
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ReacX Pharmaceuticals, Inc.
Substance Dependence
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00513279
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
EtOH Interaction Study
This study will investigate the possible effects of alcohol in combination with GSK598809 on the central nervous system in 20 healthy male and female volunteers, between 18 and 65 years of age.
- Trial name
- NCT00887367
- Testing
- GSK598809, Ethanol
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Use Disorders
Contingency Management Using Smartphone App in Patients With SUD
The purpose of this research study is to test the acceptance and efficacy of a smartphone app (DynamiCare Rewards) for patients with substance use disorder (SUD) who are in active treatment and recovery at BrightView.
- Trial name
- NCT04162132
- Testing
- Smartphone app
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- BrightView LLC
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00248092
- Testing
- NRP104
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
Evaluation of Abuse Potential of Sativex
Abuse Potential of Sativex
This crossover study with six treatment sessions is to evaluate the abuse potential of three doses of Sativex as compared to Marinol and placebo, in subjects with a history of recreational marijuana use.
- Trial name
- NCT01323569
- Testing
- Sativex, Marinol
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Substance Dependence
Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement
This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese.
- Trial name
- NCT01039454
- Testing
- GSK598809 Capsules
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health
Opioid Use Disorder
Brain Training for Substance Use Disorders
Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game…
- Trial name
- NCT06870110
- Testing
- Bias Modification Biofeedback
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurotype Inc.